Provided by Tiger Trade Technology Pte. Ltd.

JUNSHI BIO

17.380
-0.510-2.85%
Volume:1.86M
Turnover:33.15M
Market Cap:17.85B
PE:-19.98
High:18.500
Open:18.400
Low:17.380
Close:17.890
52wk High:31.800
52wk Low:15.250
Shares:1.03B
HK Float Shares:260.00M
Volume Ratio:2.10
T/O Rate:0.72%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.870
ROE:-9.32%
ROA:-2.89%
PB:2.57
PE(LYR):-19.98
PS:5.04

Loading ...

JUNSHI BIO Shares Surge Over 5% on Inclusion of Junmaikang® in National Essential Drug List

Stock News
·
Jul 10

JUNSHI BIO Seeks Shareholders’ Nod for 10% H-Share Buyback Mandate

Bulletin Express
·
Jul 08

Junshi Biosciences to Seek H-Share Repurchase Mandate at 27 July 2026 EGM

Bulletin Express
·
Jul 08

Junshi Biosciences Sets 22–27 July 2026 H-Share Register Closure to Confirm First EGM Entitlements

Bulletin Express
·
Jul 08

Possible Turnaround For Shanghai Junshi Biosciences Insiders, Still Down CN¥4.6m

Simply Wall St.
·
Jul 05

Junshi Bio June 2026 Monthly Return: Share Capital Unchanged, 37.91 Million Options Outstanding

Bulletin Express
·
Jul 03

Shanghai Junshi Biosciences HK Shares Hit 4-week Peak on Fosun's Licensing Deal

Reuters
·
Jul 02

JUNSHI BIO Shares Surge Over 11% on Licensing Agreement for Novel Antibody

Stock News
·
Jul 02

Junshi Biosciences licenses anti-IL-17A antibody “Roconkibart” to Fosun Wanbang in RMB1.34 billion deal for Greater China

Bulletin Express
·
Jul 01

Shanghai Junshi Biosciences - Will Grant Fosun Wanbang Right to Develop, Others, Roconkibart ("js005") in Greater China Region

THOMSON REUTERS
·
Jul 01

Chinese Biopharma Stocks Rally as Investors Favor Healthcare over AI

Dow Jones
·
Jun 29

Junshi Bio appoints Chen Liang as Independent Non-Executive Director; committee leadership realigned

Bulletin Express
·
Jun 26

JUNSHI BIO Appoints Chen Liang as Independent Non-Executive Director

Stock News
·
Jun 26

Junshi Bio Updates Board Composition and Committee Leadership

Bulletin Express
·
Jun 26

JUNSHI BIO Shares Surge Over 5% Following Strategic Investment in Shanghai Biopharma Firm for ADC and Multispecific Antibody Development

Stock News
·
Jun 12

Hong Kong Stocks Decline Amid Tech Selloff; Shanghai Junshi Biosciences Slips on Oncology Venture

MT Newswires Live
·
Jun 08

Junshi Biosciences Takes Stake in Oncology JV via Asset Contribution

MT Newswires Live
·
Jun 08

JUNSHI BIO Tables AGM Agenda: No 2025 Dividend, Up to RMB8.50 Billion Credit, RMB5.00 Billion Guarantee Quota and Fresh Mandates for Debt and Share Issuance

Bulletin Express
·
Jun 05

Junshi Bio issues proxy form for 2025 AGM; agenda covers profit distribution, financing mandates and INED election

Bulletin Express
·
Jun 05

Junshi BIO to Contribute Patent Equipment Valued at RMB 53.08 Million for Stake in Shanghai Zhiyu Biopharma, Expanding into ADC and Multi-Specific Antibody R&D

Stock News
·
Jun 05